Cryoport, Inc. Q3 2025 Earnings Recap

CYRX Q3 2025 November 6, 2025

Get alerts when CYRX reports next quarter

Cryoport delivered strong third-quarter performance, achieving double-digit growth in both its Life Sciences Services and Products segments, bolstered by significant demand for cell and gene therapy support.

Earnings Per Share Beat

$-0.18 vs $-0.23 est.

+21.7% surprise

Revenue Beat

44233000 vs 42923880 est.

+3.0% surprise

Market Reaction

1-Day +0.6%

5-Day +5.16%

30-Day +19.93%

See CYRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue from commercial cell and gene therapy surged 36% year-over-year to $8.3 million, reflecting robust market adaptation.
Overall Life Sciences revenue rose 16% year-over-year, accounting for 55% of total revenue from continuing operations.
The launch of next-generation cryogenic systems and new cryopreservation services positions Cryoport for further growth and market leadership.
A new state-of-the-art global supply chain center opened in Paris enhances service capabilities in European and global markets.
Strategic partnership with DHL Group poised to bolster market presence in the APAC and EMEA regions over time.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CYRX on AllInvestView.